Fibrosoft: A novel non-surgical treatment of fibromatosis, including Dupuytren’s, Ledderhose’s and Peyronie’s diseases. Introduction: Subcutaneous scarring and contracture affecting the hands (Dupuytren’s), feet (Ledderhose’s) and penis (Peyronie’s) are common. The incidence of Dupuytren’s contracture worldwide in individuals over 65 years is 32-35%. This incidence is higher in European countries. Conservatively, 28.8 million individuals have Dupuytren’s contracture in the USA, UK and Australia alone. Surgery is the gold standard and recovery painful and arduous. Solution: Fibrosoft- a novel nonsurgical intralesional injection. The formulation offers a safer and efficacious treatment of fibromatosis. 270+ patients have been treated with 30% improvement following the first injection. The treatment is safe with no serious adverse events (SAEs) observed and zero CTN (Clinical trial notification). Over 90% of patients return periodically for further injections to improve the symptoms. Competitor: Xiaflex marketed by Endo Pharmaceuticals for treating Dupuytren’s contracture and Peyronie’s disease. Xiaflex is an enzyme - collagenase clostridium histolyticum – which is injected into the affected areas and weakens the fibrotic scar. The treatment is often painful, has a high recurrence rate and can cause side effects such as swelling, tendon rupture, nerve injury, bruising, and allergic reaction. Xiaflex is expensive with a course of treatment costing more than $3,000. It is available only in the United States. It is not available in Europe, Canada or Australia. Our advantage: Significantly less side effects and lower cost. Patent status: • USA: US Patent No. 12,280,095 issued 22 April 2025; Continuation application No.19/083,699 filed 19 March 2025. • Europe: European Application No. 22859663.1 - Under accelerated prosecution. • Australia: Australian Patent No. 2022335159 granted on 8 February 2024; Australian Divisional Application No. 2024200488 filed 25 January 2024 • Projected Patent Expiry Date: 25 August 2042-